Alivira Animal Health Completes Acquisition of BioForLife Italia for Shares
On July 21, 2026, a transaction was executed marking a significant step in Viyash Scientific Limited's international expansion. The acquisition involved Alivira Animal Health Limited, a wholly owned subsidiary of Viyash Scientific Limited, which finalized the purchase of 100% of the issued and outstanding share capital of BioForLife Italia S.r.l., based in Milan, Italy.The Sale and Purchase Agreement (SPA) established the base aggregate consideration for the acquisition at approximately EUR 16.976 million, subject to adjustment for the net financial position as stipulated by the SPA. The payment structure is divided into a portion paid at closing and a retained amount linked to specific conditions.
According to the agreement terms, EUR 15.0 million was payable upon completion of the transaction at closing. The remaining approximately EUR 1.976 million has been structured as retained or deferred consideration. This deferred payment mechanism has been revised as part of the final agreed terms and is tied to specified contractual continuation conditions within the SPA.
The successful completion of this acquisition remains contingent on several key regulatory approvals. These conditions include the receipt of the necessary Italian FDI / Golden Power clearance, alongside the satisfaction or valid waiver of other conditions detailed in the SPA.
Prior details regarding the proposed acquisition were disclosed previously. The current update focuses specifically on confirming the definitive execution of the transaction documentation and detailing the revised deferred consideration mechanism.
VIYASH Stock Price Movement
Viyash Scientific Limited shares settled higher today, edging up 0.36% to close at ₹265.15 in the post-market session. The equity traded within a moderate range, hitting a low of ₹259.05 and peaking at ₹267.25 during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.